首页> 外文期刊>CNS neuroscience & therapeutics. >microRNA‐139‐5p confers sensitivity to antiepileptic drugs in refractory epilepsy by inhibition of MRP1
【24h】

microRNA‐139‐5p confers sensitivity to antiepileptic drugs in refractory epilepsy by inhibition of MRP1

机译:MicroRNA-139-5P通过抑制MRP1将难治性癫痫中的抗癫痫药物的敏感性赋予敏感性药物

获取原文
           

摘要

Aim Drug resistance is an intractable issue urgently needed to be overcome for improving efficiency of antiepileptic drugs in treating refractory epilepsy. microRNAs (miRNAs) have been proved as key regulators and therapeutic targets in epilepsy. Accordingly, the aim of the present study was to identify a novel differentially expressed miRNA which could improve the efficiency of antiepileptic drugs during the treatment of refractory epilepsy. Methods and Results Serum samples were collected from children with refractory epilepsy. An in vivo refractory epilepsy model was developed in SD rats by electrical amygdala kindling. We identified that miR‐139‐5p was decreased and multidrug resistance‐associated protein 1 (MRP1) was remarkably upregulated in the serum samples from children with refractory epilepsy and the brain tissues from rat models of refractory epilepsy. After phenobarbitone injection in rat models of refractory epilepsy, the after discharging threshold in kindled amygdala was detected to screen out drug‐resistant rats. Dual‐luciferase reporter gene assay demonstrated that MRP1 was a target of miR‐139‐5p. In order to evaluate the effect of miR‐139‐5p/MRP1 axis on drug resistance of refractory epilepsy, we transfected plasmids into the hippocampus of drug‐resistant rats to alter the expression of miR‐139‐5p and MRP1. TUNEL staining and Nissl staining showed that miR‐139‐5p overexpression or MRP1 downregulation could reduce the apoptosis and promote survival of neurons, accompanied by alleviated neuronal damage. Conclusion Collectively, these results suggest an important role of miR‐139‐5p/MRP1 axis in reducing the resistance of refractory epilepsy to antiepileptic drugs.
机译:目的耐药性是迫切需要克服难以应变的问题,以便在治疗难治性癫痫中提高抗癫痫药物的效率。 MicroRNA(miRNA)被证明是癫痫中的关键调节因子和治疗靶标。因此,本研究的目的是鉴定一种新型差异表达的miRNA,其在治疗难治性癫痫时可以提高抗癫痫药物的效率。从难治性癫痫的儿童收集方法和结果血清样品。在SD大鼠中,通过电动Amygdala点燃开发了体内难治性癫痫模型。我们发现MiR-139-5P减少,多药抗性相关蛋白1(MRP1)在来自难治性癫痫症儿童的血清样本中显着上调,来自来自难治性癫痫的大鼠模型的大鼠模型。苯吡酮在大鼠难治性癫痫大鼠模型后,检测点燃杏仁盐中的排出阈值以筛分耐药大鼠。双荧光素酶报告总基因测定证明MRP1是miR-139-5p的靶标。为了评估miR-139-5P / MRP1轴对耐火性癫痫的耐药性的影响,我们将质粒转染到耐药大鼠海马中,以改变miR-139-5p和MRP1的表达。 TUNEL染色和NISSL染色表明,MIR-139-5P过表达或MRP1下调可降低细胞凋亡并促进神经元的存活,伴有缓解神经元损伤。结论集体,这些结果表明MIR-139-5P / MRP1轴在降低耐火性癫痫到抗癫痫药物的抗性方面的重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号